Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENTIAL trial of dual antiplatelet therapy after reperfusion-treated mild ischemic stroke
2026-525681-22-00Phase 3Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clopidogrel and aspirin in ischemic stroke (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Recurrent ischemic stroke. Planned start Sep 2026; status: authorised.
02
Drugs
clopidogrelaspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2026-525681-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525681-22-00.